



***In-vitro* Anti-diabetic Evaluation of Sambirani Poo Kuligai by Alpha Amylase Enzyme Inhibition Assay**

A. Dharani^{a+++}, M. Muthupandiyan^{b++} and R. Menaka^{a#}

^a Department of PG Pothu Maruthuvam, Govt Siddha Medical College, Chennai-106, India.

^b Department of PG Noi Nadal, Govt Siddha Medical College, Chennai-106, India.

Authors' contributions

This work was carried out in collaboration among all authors. Author AD conceived and designed the study, wrote the original draft. Author MM wrote the paper and prepared the visualizations. Author RM administered the study. All authors read and approved the final manuscript.

Article Information

DOI: <https://doi.org/10.9734/jamps/2024/v26i7701>

Open Peer Review History:

This journal follows the Advanced Open Peer Review policy. Identity of the Reviewers, Editor(s) and additional Reviewers, peer review comments, different versions of the manuscript, comments of the editors, etc are available here: <https://www.sdiarticle5.com/review-history/119685>

Original Research Article

Received: 23/05/2024

Accepted: 25/07/2024

Published: 29/07/2024

ABSTRACT

Background: Diabetes mellitus (DM) is a metabolic disorder characterized by chronic hyperglycemia or increased blood glucose levels with disturbances in carbohydrate, fat and protein metabolism resulting from absolute or relative lack of insulin secretion. The Siddha system of medicine is a traditional medical system that uses a scientific and holistic approach to provide preventive, promotive, curative, rejuvenating and rehabilitative health care. According to Siddha literature, diabetes is known as Innippu Neer, Madhumegam and Neerizhivu. The various reasons for the cause of this disease are attributed to food, habits and lifestyle changes and also due to hereditary causes. The inhibition of alpha amylase enzyme involved in the digestion of

⁺⁺ PG Scholar;

[#] Lecturer;

^{*}Corresponding author: E-mail: dhara987@gmail.com;

Cite as: Dharani, A., M. Muthupandiyan, and R. Menaka. 2024. "In-Vitro Anti-Diabetic Evaluation of Sambirani Poo Kuligai by Alpha Amylase Enzyme Inhibition Assay". *Journal of Advances in Medical and Pharmaceutical Sciences* 26 (7):49-56. <https://doi.org/10.9734/jamps/2024/v26i7701>.

carbohydrates can significantly reduce the postprandial increase of blood glucose and therefore can be an important strategy in the management of blood glucose level in type-2 diabetic and borderline patients.

Aim & Objective: This study aimed to evaluate the in vitro alpha-amylase inhibitory effect of Sambirani Poo Kuligai (SPK), a Siddha formulation, to assess its potential anti-diabetic properties.

Methods: Alpha-amylase inhibitory activity was assessed using a spectrophotometric assay.

Results: SPK exhibited alpha-amylase inhibitory potential, with a maximum inhibition of about $48.67\% \pm 4.097$ and a corresponding IC₅₀ value of 578.6 ± 44.75 µg/mL.

Conclusion: This in vitro study demonstrates that the Siddha formulation Sambirani Poo Kuligai (SPK) exhibits alpha-amylase inhibitory activity, suggesting its potential anti-diabetic properties.

Keywords: Siddha; sambirani poo kuligai; anti-diabetic; in-vitro alpha amylase inhibition assay.

1. INTRODUCTION

Diabetes mellitus (DM) is a metabolic disorder characterized by chronic hyperglycemia or increased blood glucose levels with disturbances in carbohydrate, fat and protein metabolism resulting from absolute or relative lack of insulin secretion [1]. It is estimated that 537 million (10.5%) individuals (those aged 20–79 years) worldwide are currently managing the disease. In 2021, the International Diabetes Federation (IDF) approximated that there were 537 million individuals living with diabetes, making up 10.5% of the global population, resulting in global healthcare expenses amounting to \$966 billion. This health cost is predicted to rise to more than \$1054 billion by 2045. It is alarming that the prevalence of DM is anticipated to increase to 643 million (11.3%) by 2030 and 783 million (12.2%) by 2045 [2].

The Siddha system of medicine is a traditional medical system that uses a scientific and holistic approach to provide preventive, promotive, curative, rejuvenating and rehabilitative health care. The word siddha is derived from the Tamil word siddhi, which means “to achieve” or “perfection” or “heavenly bliss” [3]. According to Siddha literature, diabetes is known as Innippu Neer, Madhumegam and Neerizhivu. The various reasons for the cause of this disease are attributed to food, habits, and lifestyle changes and also due to hereditary causes. Vatham, Pitham and Kapham are the basic principles of Siddha medicine which play a vital role in the pathology of Madhumegam [4].

“Amylase inhibitors are also known as starch blockers because they contain substances that prevent dietary starches from being absorbed by the body. Starches are complex carbohydrates that cannot be absorbed unless they are the first broken down by the digestive enzyme amylase

and other secondary enzymes. Salivary and pancreatic amylases catalyze the hydrolysis of glycosidic linkages in starch and other related polysaccharides, their inhibition have been theorized to have beneficial therapeutic effects by reducing carbohydrate-induced hyperglycemia and hyperinsulinemia” [3].

The inhibition of alpha amylase enzyme involved in the digestion of carbohydrates can significantly reduce the postprandial increase of blood glucose and therefore can be an important strategy in the management of blood glucose level in type-2 diabetic and borderline patients [5]. In vitro study, extracts of piper betel and syzygium aromaticum (clove) have potential alpha amylase and alpha glucosidase inhibitory activity [6,7]. Based on the previous studies, SPK has the possibility of having the same pharmacological activity as alpha amylase inhibitor for potential anti-diabetic agent, but such tests have not been conducted. This research purpose is to investigate *In-vitro* alpha amylase enzyme inhibitor of SPK.

2. MATERIALS AND METHODS

a) Ingredients of the Test Drug

- 1) Sambirani (benzoin)
- 2) Kirambu (clove)
- 3) Korosanai (koroचना)
- 4) Vetrilai (piper betle)

The reference for this preparation was taken from the classic siddha text, Agathiyar Paripooranam 400” [8]. The trial drug was prepared as per a Standard Operative Procedure (SOP).

b) Drug Authentication

The requisite raw drugs were procured from a well reputed indigenous raw drug shop. The

herbal raw drugs were authenticated by the Botanist of Government Siddha Medical College, Chennai and the mineral drugs were authenticated by the HOD of *Gunapadam* Department of Govt. Siddha Medical College, Chennai.

c) Purification of Raw Drugs

Herbal and mineral drugs underwent purification as per "*Sikitcha Ratna Deepam Ennum VaidhiyaNool*" [9] and "*Gunapadam Thatthu Jeeva Vaguppu*" respectively.

d) Preparation of the Drug

After being well-powdered, the purified benzoin was added to a tiny saucepan. Another large pot had a piece of paper stuck to its inside. With their

mouths facing one other, the large pot was positioned on top of the small pot. Seven layers of dirty, wet cloth were used to close the spaces between their jaws, and the material was left to dry. After that, it underwent a 12-hour sublimation process. To cut down on heat, the pot was left undisturbed once the sublimation process was complete. Following the seal's opening, the sublimed product was gathered and scrapped. After finely ground clove, it was sieved through a white cloth. Korochana also was powdered well. Clove powder and Korochana powder were added along with the sublimate. Then all these substances were grounded well with Piper betel leaf juice for 48 minutes. The paste was rolled into pills to the size of the seeds of *Abrus precatorius* which was equivalent to 130mg and dried in the shade and bottled up.

Table 1. Purification of raw drugs

S.No	Name of the Drug	Purification
1	Sambirani	The gums were purified by removing the sand, dust and odd particles
2	Kirambu	The flower buds were removed and fried slightly
3	Korosanai	The unwanted substances were removed Test for korosanai: On piercing a red hot needle into korosanai, it shows the deposition of yellow material and emission of yellow fumes
4	Vetrilai	The stalk and the middle vein were removed

Table 2. Raw drug's botanical name, family and part used

S.No	Name of the Raw Drug	Botanical/ Zoological Name [10]	Family	Part Used
1	Sambirani	<i>Styraxbenzoin, Dryand</i>	Styracaceae	Resin
2	Kirambu	<i>Syzygiumaromaticum, Linn</i>	Myrtaceae	Dried Flower buds
3	Korosanai	<i>Felbovinumpurifactum(purified ox bile or ox gall)</i>	NA	NA
4	Vetrilai	<i>Piper betle, Linn</i>	Piperaceae	Leaves

Table 3. Actions and chemical constituents of raw drugs

S. No	Name of the Drug	Actions	Chemical Constituents
1	Sambirani	Stimulant [10]	Cinnamic acid, benzoic acid, bensylbenzoate, lignans, vanillin, benzaldehyde [11]
2	Kirambu	Anti-diabetic, Hepatoprotective, [12] Anti spasmodic [10]	B caryophyllene, eugenol, acetophenone, eugenyl acetate, α humulene, γ cadinene, α phellandrene, rhammetin, kaempferol, gallic acid, vanillin [13]
3	Korosanai	Anti-spasmodic [14]	Cholic acid, chenodeoxycholic acid, biliverdin, phospholipids, cholesterol [15]
4	Vetrilai	Stimulant, Carminative, Anti-hypercholesterolemic, [16] Anti-oxidant, Anti-diabetic [17,18]	Arecoline, choline, eugenol, chavicol, caryophyllene, limonene, allylpyrocatechol [19]

Sample of 10 gram of study medicine was sent to the Noble Research Solutions, Chennai, to evaluate the alpha amylase inhibitory activity.

In-vitro Alpha Amylase Inhibition Study

Method Adopted: The spectrophotometric assay method.

The enzyme α -amylase (0.5 U/ml) was prepared by mixing 3.24 mg of α -amylase in 100 ml of phosphate buffer (pH 6.9). Test Sample (SPK) was prepared in the serial dilution of the concentration ranges from 100,200,300,400 and 500 μ g/ml using DD water. Acarbose 100 μ g/ml used as a reference standard. About 600 μ l of test sample were added to 30 μ l of α -amylase enzyme solution and incubated at 37°C for 15 min. To this reaction mixture, 370 μ l of substrate, 2-Chloro-4-Nitrophenyl- α -Maltotrioxide (CNP₃-0.5 mg/ml) was added, mixed and for incubated 37°C for 10 min. Finally, absorbance was measured at 405 nm against blank in spectrophotometer. A control reaction was carried out without the test sample.

Percentage inhibition was calculated by the following formula.

Percentage inhibition

$$\% \text{inhibition} = \frac{\text{Absorbance}_{\text{Control}} - \text{Absorbance}_{\text{Test}}}{\text{Absorbance}_{\text{Control}}} \times 100$$

Table 4. Percentage inhibition of test drug SPK on Alpha Amylase enzyme Inhibition Study

Concentration (μ g/ml)	% Inhibition of SPK
100 μ g/ml	16.77 \pm 3.228
200 μ g/ml	25.37 \pm 8.351
300 μ g/ml	35.39 \pm 19.16
400 μ g/ml	42.38 \pm 11.04
500 μ g/ml	48.67 \pm 4.097
Standard	94.02 \pm 4.742
Acarbose	

Data are given as Mean \pm SD (n=3)

Table 5. IC50 Values for Alpha Amylase Enzyme inhibition by SPK and STD

Test Drug / Standard	IC50 Value of Alpha Amylase enzyme inhibition \pm SD (μ g /ml)
SPK	578.6 \pm 44.75
Standard-Acarbose	26.41 \pm 2.526

Data are given as Mean \pm SD (n=3)




Fig. 1. Percentage inhibition of test drug SPK and Standard on Alpha Amylase Enzyme Inhibition Assay

3. RESULTS AND DISCUSSION

This study investigated the alpha- amylase inhibition activity of SPK as a potential therapeutic strategy for type 2 diabetes. Our findings demonstrated that SPK exhibited significant alpha-amylase inhibitory potential with the maximum inhibition of about $48.67 \pm 4.097\%$ and the corresponding IC_{50} is $578.6 \pm 44.75 \mu\text{g}/\text{ml}$. Standard acarbose exhibited significant inhibition in alpha amylase enzyme with the maximum inhibition of about $94.02 \pm 4.742\%$ and the corresponding IC_{50} is $26.41 \pm 2.526 \mu\text{g}/\text{ml}$.

The alpha amylases are the calcium metalloenzymes which can't function in the absence of calcium. There are many digestive enzymes in humans and among them the most important one is pancreatic alpha – amylase, that act as a catalysis in the reaction which involves the hydrolysis of the alpha-1,4 glycosidic linkages of the starch, amylopectin, amylose, glycogen and numerous maltodextrins and is responsible for starch digestion. The large molecules like starch cannot cross the blood brain barrier as glucose has to reach the brain thus; to overcome this problem alpha-amylase cleaves the large starch molecules into smaller fragments of sugars in order to cross the blood brain barrier. If there will be excess conversion of starch to sugars, it will increase the sugar level in blood, then the role of insulin will come into action by ordering cells to metabolize the excess sugar moieties and store as energy sources i.e., glycogen. This cycle is endlessly happening in a healthy person. But in some cases, due to excess activity of amylase enzyme and insulin deficiency or resistance to insulin, level of blood glucose arises which might results in hyperglycaemia [20].

In the management of post prandial hyperglycemia (PPH) enhancement of insulin secretion, insulin sensitivity or reducing glucose production in the liver are achieved by inhibiting the activity of alpha amylase and alpha glucosidase, the major risk factor for cardiovascular complication in DM patient is glycation end product(a metabolite), hence by reducing PPH reduces this metabolite [21].

Among four ingredients of Sambirani Poo Kuligai, styrax benzoin contains free balsamic acid chiefly cinnamic 10% and benzoic acid 6% and vanillin. In a study conducted by Veronica F Salau et al, the fructose-streptozotocin induced diabetic rats were given **vanillin** at a low

(150mg/kg body weight) or high (300mg/kg body weight) dose of vanillin for 5 weeks intervention period and there levels of blood glucose observed significant reduction in blood given [22]. Rahman M Hafizur et al. conducted a study on mechanism of anti-diabetic activity of **cinnamic acid** in in-vitro and in-vivo non obese type 2 diabetic rats and finally concluded that cinnamic acid exerts antidiabetic activity by improving glucose tolerance in vivo and stimulating insulin secretion *In-vitro* [23].

Sabbir Ahmed et al conducted a study on molecular docking and dynamics stimulation of natural compounds from betel leaves (piper betle.),In this study, a new molecule, apigenin-7-O-glucoside (screened out from 123 compounds of *Piper betle* L.), which inhibited both enzymes (alpha-amylase and alpha-glucosidase) activity by binding with its active sites, ASP-197, GLU-233, and ASP-300 and ASN-258, ASP-327, ILE-143, ASP-382, respectively [24]. Sindhu S Nair et al, conducted in-vitro studies on alpha amylase and alpha glucosidase inhibitory activities of selected plant extracts, among them methanolic extracts of **piper betle** showed that (84.63 $\mu\text{g}/\text{mL}$) exhibited 50% alpha amylase inhibition activity at the mentioned concentrations. The alpha glucosidase IC_{50} for the plant extracts Piper betle was found to be $96.56 \pm 12.93 \mu\text{g}/\text{mL}$ respectively [6]. Hafiz Muhammad Arsalan conducted a study in 2019. In this study, ethanolic extract of Piper betle leaf was used (300 mg/kg). Diabetes was induced in male albino rats by using Alloxan (150 mg/kg). Glutathione (GSH), Catalase (CAT), Malondialdehyde (MDA), Nitric oxide (NO), micronutrients (Vitamin A, Vitamin C and Vitamin E), serum glucose level and Advance glycation end products (AGE's) were estimated. The results showed that levels of the Malondialdehyde (0.087, 0.151 and 0.104 respectively), Advance glycation end products (0.026, 0.053, 0.025) and Nitric oxide (0.07, 0.438, 0.190) were decreased while level of the GSH (0.184, 0.188, 0.207), CAT (0.087, 0.031, 0.091) and vitamin A (0.196, 0.136, 0.178), E (0.199, 0.140, 0.179) and C (0.163, 0.120, 0.164) were increased after administration of Piper betle leaf extract. Blood glucose level was also found to be decreased. These findings suggest that Piper betle leaves may be a potential antidiabetic agent due to their ability to lower blood glucose levels [25].

Stephen Adeniyi Adefegha et al. conducted a study on In vitro inhibition activity of polyphenol-

rich extracts from *Syzygium aromaticum* (L.) Merr. & Perry (Clove) buds against carbohydrate hydrolyzing enzymes linked to type 2 diabetes and Fe²⁺-induced lipid peroxidation in rat pancreas. The result revealed that both extracts inhibited alpha-amylase and alpha-glucosidase in a dose-dependent manner. However, the alpha-glucosidase inhibitory activity of the extracts were significantly ($P<0.05$) higher than their alpha-amylase inhibitory activity. The free phenolics (31.67 mg/g) and flavonoid (17.28 mg/g) contents were significantly ($P<0.05$) higher than bound phenolic (23.52 mg/g) and flavonoid (13.70 mg/g) contents [7]. Hafizah Umaira Tahir et al. conducted a study in 2016, to evaluate antidiabetic potential of *Syzygium aromaticum* essential oils and their emulsions by alpha amylase inhibition assay. Antidiabetic activity of *S. aromaticum* was examined in dose dependent mode (1 to 100 µg/mL). The maximum antidiabetic activity for *S. aromaticum* essential oils was noted at the highest dose (100 µg/mL). Five emulsions of different concentrations for *S. aromaticum* (A1 to A5) essential oil was formulated. Among different emulsions, A5 of *S. aromaticum* essential oil exhibited a maximum antidiabetic activity with 95.30 % inhibition of α-amylase. Moreover, the analysis of essential oils showed that eugenol (18.7%) was the major component of *S. aromaticum* essential oils [26].

Candra D. Hamdin et al conducted the study in 2019. The study was designed to investigate the effects of eugenol on the fasting blood glucose (FBG) and histological pattern of pancreas and liver of alloxan-diabetic rats. Eugenol was extracted and isolated from cloves leaves oil and was then screened by in vivo model of diabetic rats. Diabetic condition was induced with alloxan monohydrate (125 mg/kgbw, iv). Rats were divided into five groups: eugenol with 3 serial doses of 5 mg/kgbw (D1), 10 mg/kgbw(D2), 15 mg/kgbw (D3); positive control- glibenclamid 1.35 mg/kgbw (D4); normal control (D5) and negative control- CMC-Na 0,5% (D6). The treatments were performed daily for 15 days. Fasting blood glucose (FBG) level of D1 to D5 before treatment was 404, 363, 319, 313, and 113 mg/dL, respectively; and after 15 days were reduced to be 294, 181, 97, 112, and 94 mg/dL, respectively. Statistically, blood glucose reduction of D1, D2, and D3 were significant ($P>0,05$) compared to positive control. D3 seems to be effective dose causing hypoglycaemic. Histological studies of pancreas and liver indicated that D3 may improve the morphology of

Langerhans and liver into normal condition [27].

Studies mentioned in this review, reveal that among the four ingredients of Sambirani Poo Kuligai, Piper betle, syzygium aromaticum and styrax benzoin has potential anti-diabetic properties. In the present study, the results of alpha amylase inhibitory assay displayed a considerable inhibitory activity with the extract of Sambirani Poo Kuligai. Hence it can be concluded that Sambirani Poo Kuligai is a siddha formulation with multi-nodal antidiabetic actions and may serve as a potent anti-diabetic agent [28].

4. CONCLUSION

From this study, we can state that siddha formulation Sambirani Poo Kuligai showed significant inhibition of alpha amylase enzyme activity. Thus, the siddha formulation SPK may consider as a remedy for diabetes and other insulin resistance- related diseases like polycystic ovarian syndrome; however, animal and human studies are needed to confirm this activity.

DISCLAIMER (ARTIFICIAL INTELLIGENCE)

Author(s) hereby declare that NO generative AI technologies such as Large Language Models (ChatGPT, COPILOT, etc) and text-to-image generators have been used during writing or editing of manuscripts.

CONSENT

This study did not involve human subjects and therefore does not require informed consent.

ETHICAL APPROVAL

Ethical approval was not required for this study as it did not involve human participants.

ACKNOWLEDGEMENTS

I would like to express my deepest gratitude to the esteemed lecturers of PG Pothu Maruthuvam department at Government Siddha Medical College, Chennai, for their invaluable guidance and insightful feedback. I am also immensely thankful to Dr. K. Kanakavalli, Principal of Government Siddha Medical College, Chennai, and The TamilNadu Dr. M. G. R. Medical

University for their support. Furthermore, I extend my sincere appreciation to my friends for their unwavering guidance and encouragement throughout this journey.

COMPETING INTERESTS

Authors have declared that no competing interests exist.

REFERENCES

- Narkhede MB. Investigation of *In vitro* α -amylase and α -glucosidase inhibitory activity of polyherbal extract. *Int. J. Pharm. Res. Dev.* 2011;3:97-103.
- Hossain MJ, Al-Mamun M, Islam MR. Diabetes mellitus, the fastest growing global public health concern: Early detection should be focused. *Health Science Reports.* 2024;7(3):e2004.
- Dubey NP, Dubey N. Basic principles of integrated medicine. *World Association of Integrated Medicine;* 2013.
- Logisha MS, Nivetha G, Karpagavalli K, Muthukumar NJ, Mahalakshmi MV, Meenakumari M. A Review on anti-diabetic herbs of siddha system based on their organoleptic characteristic. *International Journal of Ayurveda and Pharma Research.* 2023;87-91.
- Pillegowda-Smitha K, Srinivas-Kulashekar K, Krishnappa-Pavithra T, Srinivas-Ashok-Kumar B, Setty-Saran G. Alpha-amylase inhibitory activity of sitopaladi churna: An ayurvedic formula. *Traditional and Integrative Medicine.* 2016;40-3.
- Nair SS, Kavrekar V, Mishra A. In vitro studies on alpha amylase and alpha glucosidase inhibitory activities of selected plant extracts. *European journal of experimental biology.* 2013;3(1):128-32.
- Adefegha SA, Oboh G. *In vitro* inhibition activity of polyphenol-rich extracts from *Syzygium aromaticum* (L.) Merr. & Perry (Clove) buds against carbohydrate hydrolyzing enzymes linked to type 2 diabetes and Fe²⁺-induced lipid peroxidation in rat pancreas. *Asian Pacific Journal of Tropical Biomedicine.* 2012; 2(10):774-81.
- Mohan RC. Agasthiyar paripooranam 400 page no: 62.
- Kannuswamy Pillai C, Sikitcha Ratna Deepam Ennum Vaidhiya Nool. 2018;28,29,31.
- Vaithya Ratnam KS Murukase Muthaliyar, Gunapadam (mooligai vaguppu); 2013.
- Sohail Akhtar M, Alam T. Chemistry, biological activities, and uses of benzoin resin. In *Gums, Resins and Latexes of Plant Origin: Chemistry, Biological Activities and Uses* Cham: Springer International Publishing. 2022;1-22.
- Sammy J, Tamuno-Emine D, Nwachuku E. Evaluation of anti-diabetic, hepatoprotective and antilipidemic potentials of *Syzygium aromaticum* (Clove) on albino rat. *JOCAMR.* 2020;1:38-50.
- Nassar MI, Gaara AH, El-Ghorab AH, Farrag A, Shen H, Huq E, Mabry TJ. Chemical constituents of clove (*Syzygium aromaticum*, Fam. Myrtaceae) and their antioxidant activity. *Revista Latinoamericana de Química.* 2007; 35(3):47.
- Thiyaga Rajan LIMR.. Gunapadam part 2&3 (Thathu-Jeeva vaguppu); 2013.
- Hu PL, Yuan YH, Yue TL, Guo CF. Bile acid patterns in commercially available oxgall powders used for the evaluation of the bile tolerance ability of potential probiotics. *PLoS One.* 2018;13(3): e0192964.
- Venkadeswaran K, Muralidharan AR, Annadurai T, Ruban VV, Sundararajan M, Anandhi R, Thomas PA, Geraldine P. Antihypercholesterolemic and antioxidative potential of an extract of the plant, *Piper betle*, and its active constituent, eugenol, in triton WR-1339-induced hypercholesterolemia in experimental rats. *Evidence-Based Complementary and Alternative Medicine.* 2014;2014.
- Perumal PA, Saravanabhavan K. Antidiabetic and antioxidant activities of ethanolic extract of *Piper betle* L. leaves in catfish, *Clarias gariepinus*. *Asian J Pharm Clin Res.* 2018;11(3):194-8.
- Jing X, Sarker MM, Alam S, Gifari AJ, Akhter S, Khan F, Soma MA. *Piper betel* juice improved lipid profile and hepatic oxidative stress in high-fat-diet induced hyperlipidemic rats.
- Rekha VP, Kollipara M, Gupta BR, Bharath Y, Pulicherla KK. A review on *Piper betle* L.: nature's promising medicinal reservoir. *American Journal of Ethnomedicine.* 2014;1(5):276-89
- Agarwal P, Gupta R. Alpha-amylase inhibition can treat diabetes mellitus. *Res. Rev. J. Med. Health Sci.* 2016;5(4):1-8.

21. Kaantham L, Mohan S. Screening of anti-diabetic potential of the siddha formulation uloga chenduram by *In-vitro* alpha-amylase and alpha- glucosidase enzyme inhibition assay; 2020.
22. Salau VF, Erukainure OL, Olofinsan KO, Msomi NZ, Ijomone OM, Islam MS. Vanillin improves glucose homeostasis and modulates metabolic activities linked to type 2 diabetes in fructose–streptozotocin induced diabetic rats. *Archives of Physiology and Biochemistry*. 2024;130(2): 169-82.
23. Hafizur RM, Hameed A, Shukrana M, Raza SA, Chishti S, Kabir N, Siddiqui RA. Cinnamic acid exerts anti-diabetic activity by improving glucose tolerance in vivo and by stimulating insulin secretion *In vitro*. *Phytomedicine*. 2015;22(2):297-300.
24. Ahmed S, Ali MC, Ruma RA, Mahmud S, Paul GK, Saleh MA, Alshahrani MM, Obaidullah AJ, Biswas SK, Rahman MM, Rahman MM. Molecular docking and dynamics simulation of natural compounds from betel leaves (*Piper betle* L.) for investigating the potential inhibition of alpha-amylase and alpha-glucosidase of type 2 diabetes. *Molecules*. 2022; 27(14):4526.
25. Arsalan HM. Evaluation of antioxidative and antidiabetic potential of *Piper betle* leaf in alloxan induced diabetic albino Rats. *Biologia (Pakistan)*. 2019;65:317-21.
26. Tahir HU, Sarfraz RA, Ashraf A, Adil S. Chemical composition and antidiabetic activity of essential oils obtained from two spices (*Syzygium aromaticum* and *Cuminum cyminum*). *International Journal of Food Properties*. 2016;19(10):2156-64.
27. Hamdin CD, Utami SW, Muliastari H, Prasedya ES, Sudarma I. Histological pattern on pancreas and liver of diabetic rats after treatment of eugenol isolated from leaves of *Syzygium aromaticum*. *InAIP Conference Proceedings* 2019;2199(1). AIP Publishing.
28. Kumar A, Lakshman K, Jayaveera KN, VB NS, Khan S, Velumurga C. *In vitro* α -amylase inhibition and antioxidant activities of methanolic extract of *Amaranthus caudatus* Linn. *Oman medical journal*. 2011;26(3):166.

Disclaimer/Publisher's Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of the publisher and/or the editor(s). This publisher and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

© Copyright (2024): Author(s). The licensee is the journal publisher. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<http://creativecommons.org/licenses/by/4.0>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Peer-review history:

The peer review history for this paper can be accessed here:

<https://www.sdiarticle5.com/review-history/119685>